Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Dermatology CRO Market 

5.1. COVID-19 Landscape: Dermatology CRO Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Dermatology CRO Market, By Service

8.1. Dermatology CRO Market, by Service, 2023-2032

8.1.1 Project Management/Clinical Supply Management

8.1.1.1. Market Revenue and Forecast (2021-2032)

8.1.2. Data Management

8.1.2.1. Market Revenue and Forecast (2021-2032)

8.1.3. Regulatory/Medical Affairs

8.1.3.1. Market Revenue and Forecast (2021-2032)

8.1.4. Regulatory/Medical Affairs

8.1.4.1. Market Revenue and Forecast (2021-2032)

8.1.5. Clinical Monitoring

8.1.5.1. Market Revenue and Forecast (2021-2032)

8.1.6. Quality Management/Assurance

8.1.6.1. Market Revenue and Forecast (2021-2032)

8.1.7. Bio-statistics

8.1.7.1. Market Revenue and Forecast (2021-2032)

8.1.8. Investigator Payments

8.1.8.1. Market Revenue and Forecast (2021-2032)

8.1.9. Laboratory

8.1.9.1. Market Revenue and Forecast (2021-2032)

8.1.10. Clinical Monitoring

8.1.10.1. Market Revenue and Forecast (2021-2032)

8.1.11. Technology

8.1.11.1. Market Revenue and Forecast (2021-2032)

8.1.12. Clinical Monitoring

8.1.12.1. Market Revenue and Forecast (2021-2032)

8.1.13. Others

8.1.13.1. Market Revenue and Forecast (2021-2032)

Chapter 9. Global Dermatology CRO Market, By Type

9.1. Dermatology CRO Market, by Type, 2023-2032

9.1.1. Drug Discovery

9.1.1.1. Market Revenue and Forecast (2021-2032)

9.1.2. Preclinical

9.1.2.1. Market Revenue and Forecast (2021-2032)

9.1.3. Clinical

9.1.3.1. Market Revenue and Forecast (2021-2032)

Chapter 10. Global Dermatology CRO Market, By Phase Type 

10.1. Dermatology CRO Market, by Phase Type, 2023-2032

10.1.1. Phase I

10.1.1.1. Market Revenue and Forecast (2021-2032)

10.1.2. Phase II

10.1.2.1. Market Revenue and Forecast (2021-2032)

10.1.3. Phase III

10.1.3.1. Market Revenue and Forecast (2021-2032)

10.1.4. Phase IV

10.1.4.1. Market Revenue and Forecast (2021-2032)

Chapter 11. Global Dermatology CRO Market, Regional Estimates and Trend Forecast

11.1. North America

11.1.1. Market Revenue and Forecast, by Service (2021-2032)

11.1.2. Market Revenue and Forecast, by Type (2021-2032)

11.1.3. Market Revenue and Forecast, by Phase Type (2021-2032)

11.1.4. U.S.

11.1.4.1. Market Revenue and Forecast, by Service (2021-2032)

11.1.4.2. Market Revenue and Forecast, by Type (2021-2032)

11.1.4.3. Market Revenue and Forecast, by Phase Type (2021-2032)

11.1.5. Rest of North America

11.1.5.1. Market Revenue and Forecast, by Service (2021-2032)

11.1.5.2. Market Revenue and Forecast, by Type (2021-2032)

11.1.5.3. Market Revenue and Forecast, by Phase Type (2021-2032)

11.2. Europe

11.2.1. Market Revenue and Forecast, by Service (2021-2032)

11.2.2. Market Revenue and Forecast, by Type (2021-2032)

11.2.3. Market Revenue and Forecast, by Phase Type (2021-2032)

11.2.4. UK

11.2.4.1. Market Revenue and Forecast, by Service (2021-2032)

11.2.4.2. Market Revenue and Forecast, by Type (2021-2032)

11.2.4.3. Market Revenue and Forecast, by Phase Type (2021-2032)

11.2.5. Germany

11.2.5.1. Market Revenue and Forecast, by Service (2021-2032)

11.2.5.2. Market Revenue and Forecast, by Type (2021-2032)

11.2.5.3. Market Revenue and Forecast, by Phase Type (2021-2032)

11.2.6. France

11.2.6.1. Market Revenue and Forecast, by Service (2021-2032)

11.2.6.2. Market Revenue and Forecast, by Type (2021-2032)

11.2.6.3. Market Revenue and Forecast, by Phase Type (2021-2032)

11.2.7. Rest of Europe

11.2.7.1. Market Revenue and Forecast, by Service (2021-2032)

11.2.7.2. Market Revenue and Forecast, by Type (2021-2032)

11.2.7.3. Market Revenue and Forecast, by Phase Type (2021-2032)

11.3. APAC

11.3.1. Market Revenue and Forecast, by Service (2021-2032)

11.3.2. Market Revenue and Forecast, by Type (2021-2032)

11.3.3. Market Revenue and Forecast, by Phase Type (2021-2032)

11.3.4. India

11.3.4.1. Market Revenue and Forecast, by Service (2021-2032)

11.3.4.2. Market Revenue and Forecast, by Type (2021-2032)

11.3.4.3. Market Revenue and Forecast, by Phase Type (2021-2032)

11.3.5. China

11.3.5.1. Market Revenue and Forecast, by Service (2021-2032)

11.3.5.2. Market Revenue and Forecast, by Type (2021-2032)

11.3.5.3. Market Revenue and Forecast, by Phase Type (2021-2032)

11.3.6. Japan

11.3.6.1. Market Revenue and Forecast, by Service (2021-2032)

11.3.6.2. Market Revenue and Forecast, by Type (2021-2032)

11.3.6.3. Market Revenue and Forecast, by Phase Type (2021-2032)

11.3.7. Rest of APAC

11.3.7.1. Market Revenue and Forecast, by Service (2021-2032)

11.3.7.2. Market Revenue and Forecast, by Type (2021-2032)

11.3.7.3. Market Revenue and Forecast, by Phase Type (2021-2032)

11.4. MEA

11.4.1. Market Revenue and Forecast, by Service (2021-2032)

11.4.2. Market Revenue and Forecast, by Type (2021-2032)

11.4.3. Market Revenue and Forecast, by Phase Type (2021-2032)

11.4.4. GCC

11.4.4.1. Market Revenue and Forecast, by Service (2021-2032)

11.4.4.2. Market Revenue and Forecast, by Type (2021-2032)

11.4.4.3. Market Revenue and Forecast, by Phase Type (2021-2032)

11.4.5. North Africa

11.4.5.1. Market Revenue and Forecast, by Service (2021-2032)

11.4.5.2. Market Revenue and Forecast, by Type (2021-2032)

11.4.5.3. Market Revenue and Forecast, by Phase Type (2021-2032)

11.4.6. South Africa

11.4.6.1. Market Revenue and Forecast, by Service (2021-2032)

11.4.6.2. Market Revenue and Forecast, by Type (2021-2032)

11.4.6.3. Market Revenue and Forecast, by Phase Type (2021-2032)

11.4.7. Rest of MEA

11.4.7.1. Market Revenue and Forecast, by Service (2021-2032)

11.4.7.2. Market Revenue and Forecast, by Type (2021-2032)

11.4.7.3. Market Revenue and Forecast, by Phase Type (2021-2032)

11.5. Latin America

11.5.1. Market Revenue and Forecast, by Service (2021-2032)

11.5.2. Market Revenue and Forecast, by Type (2021-2032)

11.5.3. Market Revenue and Forecast, by Phase Type (2021-2032)

11.5.4. Brazil

11.5.4.1. Market Revenue and Forecast, by Service (2021-2032)

11.5.4.2. Market Revenue and Forecast, by Type (2021-2032)

11.5.4.3. Market Revenue and Forecast, by Phase Type (2021-2032)

11.5.5. Rest of LATAM

11.5.5.1. Market Revenue and Forecast, by Service (2021-2032)

11.5.5.2. Market Revenue and Forecast, by Type (2021-2032)

11.5.5.3. Market Revenue and Forecast, by Phase Type (2021-2032)

Chapter 12. Company Profiles

12.1. IQVIA HOLDINGS INC.

12.1.1. Company Overview

12.1.2. Product Offerings

12.1.3. Financial Performance

12.1.4. Recent Initiatives

12.2. Covance Inc.

12.2.1. Company Overview

12.2.2. Product Offerings

12.2.3. Financial Performance

12.2.4. Recent Initiatives

12.3. Pharmaceutical Product Development, LLC (PPD)

12.3.1. Company Overview

12.3.2. Product Offerings

12.3.3. Financial Performance

12.3.4. Recent Initiatives

12.4. Parexel International Corporation

12.4.1. Company Overview

12.4.2. Product Offerings

12.4.3. Financial Performance

12.4.4. Recent Initiatives

12.5. Charles River Laboratories International, Inc.

12.5.1. Company Overview

12.5.2. Product Offerings

12.5.3. Financial Performance

12.5.4. Recent Initiatives

12.6. Icon, Plc

12.6.1. Company Overview

12.6.2. Product Offerings

12.6.3. Financial Performance

12.6.4. Recent Initiatives

12.7. Medidata Solutions, Inc.

12.7.1. Company Overview

12.7.2. Product Offerings

12.7.3. Financial Performance

12.7.4. Recent Initiatives

12.8. Syneos Health

12.8.1. Company Overview

12.8.2. Product Offerings

12.8.3. Financial Performance

12.8.4. Recent Initiatives

12.9. Pharmaron

12.9.1. Company Overview

12.9.2. Product Offerings

12.9.3. Financial Performance

12.9.4. Recent Initiatives

12.10. GVK Biosciences Private Limited

12.10.1. Company Overview

12.10.2. Product Offerings

12.10.3. Financial Performance

12.10.4. Recent Initiatives

Chapter 13. Research Methodology

13.1. Primary Research

13.2. Secondary Research

13.3. Assumptions

Chapter 14. Appendix

14.1. About Us

14.2. Glossary of Terms